Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
1.
Acta Physiol (Oxf) ; 223(3): e13051, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29423932

RESUMEN

AIM: Spinal cord injury-induced loss of skeletal muscle mass does not progress linearly. In humans, peak muscle loss occurs during the first 6 weeks postinjury, and gradually continues thereafter. The aim of this study was to delineate the regulatory events underlying skeletal muscle atrophy during the first year following spinal cord injury. METHODS: Key translational, autophagic and proteolytic proteins were analysed by immunoblotting of human vastus lateralis muscle obtained 1, 3 and 12 months following spinal cord injury. Age-matched able-bodied control subjects were also studied. RESULTS: Several downstream targets of Akt signalling decreased after spinal cord injury in skeletal muscle, without changes in resting Akt Ser473 and Akt Thr308 phosphorylation or total Akt protein. Abundance of mTOR protein and mTOR Ser2448 phosphorylation, as well as FOXO1 Ser256 phosphorylation and FOXO3 protein, decreased in response to spinal cord injury, coincident with attenuated protein abundance of E3 ubiquitin ligases, MuRF1 and MAFbx. S6 protein and Ser235/236 phosphorylation, as well as 4E-BP1 Thr37/46 phosphorylation, increased transiently after spinal cord injury, indicating higher levels of protein translation early after injury. Protein abundance of LC3-I and LC3-II decreased 3 months postinjury as compared with 1 month postinjury, but not compared to able-bodied control subjects, indicating lower levels of autophagy. Proteins regulating proteasomal degradation were stably increased in response to spinal cord injury. CONCLUSION: Together, these data provide indirect evidence suggesting that protein translation and autophagy transiently increase, while whole proteolysis remains stably higher in skeletal muscle within the first year after spinal cord injury.


Asunto(s)
Proteínas Musculares/biosíntesis , Músculo Esquelético/enzimología , Atrofia Muscular/enzimología , Proteolisis , Traumatismos de la Médula Espinal/enzimología , Adulto , Autofagosomas/metabolismo , Autofagia , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Atrofia Muscular/etiología , Complejo de la Endopetidasa Proteasomal/metabolismo , Biosíntesis de Proteínas , Proteínas Proto-Oncogénicas c-akt/metabolismo , Traumatismos de la Médula Espinal/complicaciones , Serina-Treonina Quinasas TOR/metabolismo , Ubiquitina/metabolismo
3.
Acta Physiol (Oxf) ; 192(1): 37-48, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18171428

RESUMEN

Derangements in whole body glucose and lipid metabolism, accompanied by insulin resistance, are key features of obesity and the metabolic syndrome. A role for inflammation as a causative factor is an emerging concept in the field of metabolic disease. Research has centred on identifying important inflammatory markers, and tumour necrosis factor-alpha has been highlighted as a key mediator of insulin resistance, as well as interleukin-6 (IL-6). A parallel ongoing endeavour is the unravelling of molecular mechanisms underlying the beneficial effects of physical exercise on whole body glucose and lipid metabolism. Release of IL-6 from the contracting skeletal muscle has been proposed to be one of the molecular signals promoting the beneficial exercise-induced effects. These two opposing views of IL-6 underscore that the role of IL-6 in whole body physiology is incompletely resolved. This review aims at summarizing the current data on mechanisms by which IL-6 may impact on glucose and lipid metabolism.


Asunto(s)
Glucosa/metabolismo , Interleucina-6/fisiología , Metabolismo de los Lípidos/fisiología , Animales , Diabetes Mellitus Tipo 2/fisiopatología , Ejercicio Físico/fisiología , Humanos , Resistencia a la Insulina/fisiología , Ratones , Ratones Mutantes , Obesidad/fisiopatología , Transducción de Señal/fisiología
4.
Diabetologia ; 48(6): 1173-9, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15864539

RESUMEN

AIMS/HYPOTHESIS: The aim of this study was to determine the effect of several antidiabetic agents on insulin-stimulated glycogen synthesis, as well as on mRNA expression. METHODS: Cultured primary human skeletal myotubes obtained from six healthy subjects were treated for 4 or 8 days without or with glucose (25 mmol/l), insulin (400 pmol/l), rosiglitazone (10 micromol/l), metformin (20 micromol/l) or the AMP-activated kinase activator 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) (200 micromol/l). After this, insulin-stimulated glycogen synthesis was determined. mRNA levels of the glucose transporters GLUT1 and GLUT4, the peroxisomal proliferator activator receptor gamma (PPAR gamma) co-activator 1 (PGC1) and the myocyte-specific enhancer factors (MEF2), MEF2A, MEF2C and MEF2D were determined using real-time PCR analysis after 8 days exposure to the various antidiabetic agents. RESULTS: Insulin-stimulated glycogen synthesis was significantly increased in cultured human myotubes treated with insulin, rosiglitazone or metformin for 8 days, compared with non-treated cells. Furthermore, an 8-day exposure of myotubes to 25 mmol/l glucose impaired insulin-stimulated glycogen synthesis. In contrast, treatment with AICAR was without effect on insulin-mediated glycogen synthesis. Exposure to insulin, rosiglitazone or metformin increased mRNA expression of PGC1 and GLUT4, while AICAR or 25 mmol/l glucose treatment increased GLUT1 mRNA expression. Metformin also increased mRNA expression of the MEF2 isoforms. CONCLUSIONS/INTERPRETATION: Enhanced insulin-stimulated glycogen synthesis in human skeletal muscle cell culture coincides with increased GLUT4 and PGC1 mRNA expression following treatment with various antidiabetic agents. These data show that chronic treatment of human myotubes with insulin, metformin or rosiglitazone has a direct positive effect on insulin action and mRNA expression.


Asunto(s)
Glucógeno/biosíntesis , Insulina/farmacología , Metformina/farmacología , Proteínas de Transporte de Monosacáridos/genética , Proteínas Musculares/genética , ARN Mensajero/genética , Tiazolidinedionas/farmacología , Factores de Transcripción/genética , Adulto , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/farmacología , Biopsia , Células Cultivadas , Femenino , Glucosa/farmacología , Transportador de Glucosa de Tipo 4 , Humanos , Masculino , Persona de Mediana Edad , Fibras Musculares Esqueléticas/citología , Fibras Musculares Esqueléticas/efectos de los fármacos , Fibras Musculares Esqueléticas/metabolismo , Músculo Esquelético/citología , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/metabolismo , Valores de Referencia , Ribonucleótidos/farmacología , Rosiglitazona
5.
Acta Physiol Scand ; 180(4): 395-403, 2004 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15030381

RESUMEN

AIM: We hypothesized that myogenic differentiation of HSMC would yield a more insulin responsive phenotype. METHODS: We assessed expression of several proteins involved in insulin action or myogenesis during differentiation of primary human skeletal muscle cultures (HSMC). RESULTS: Differentiation increased creatine kinase activity and expression of desmin and myocyte enhancer factor (MEF)2C. No change in expression was observed for big mitogen-activated protein kinase (BMK1/ERK5), MEF2A, insulin receptor (IR), hexokinase II, and IR substrates 1 and 2, while expression of glycogen synthase, extracellular signal-regulated kinase 1 and 2 (ERK1/2 MAP kinase) and the insulin responsive aminopeptidase increased after differentiation. In contrast to protein kinase B (PKB)a, expression of (PKB)b increased, with differentiation. Both basal and insulin-stimulated PI 3-kinase activity increased with differentiation. Insulin-mediated phosphorylation of PKB and ERK1/2 MAP kinase increased after differentiation. CONCLUSION: Components of the insulin-signalling machinery are expressed in myoblast and myotube HSMC; however, insulin responsiveness to PKB and ERK MAP kinase phosphorylation increases with differentiation.


Asunto(s)
Diferenciación Celular/fisiología , Proteínas Quinasas Activadas por Mitógenos/análisis , Músculo Esquelético/fisiología , Proteínas Serina-Treonina Quinasas , Proteínas Proto-Oncogénicas/análisis , Biomarcadores/análisis , Western Blotting/métodos , Células Cultivadas , Creatina Quinasa/metabolismo , Proteínas de Unión al ADN/análisis , Desmina/análisis , Femenino , Hexoquinasa/análisis , Humanos , Insulina/metabolismo , Proteínas de Dominio MADS , Factores de Transcripción MEF2 , Masculino , Persona de Mediana Edad , Músculo Esquelético/metabolismo , Factores Reguladores Miogénicos/análisis , Fosfatidilinositol 3-Quinasas/metabolismo , Fosforilación , Proteínas Proto-Oncogénicas c-akt , Receptor de Insulina/análisis , Factores de Transcripción/análisis
7.
J Appl Physiol (1985) ; 90(1): 29-34, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11133890

RESUMEN

Vastus lateralis muscle biopsies were obtained from endurance-trained (running approximately 50 km/wk) and untrained (no regular physical exercise) men, and the expression of an array of insulin-signaling intermediates was determined. Expression of insulin receptor and insulin receptor substrate-1 and -2 was decreased 44% (P < 0.05), 57% (P < 0.001), and 77% (P < 0.001), respectively, in trained vs. untrained muscle. The downstream signaling target, Akt kinase, was not altered in trained subjects. Components of the mitogenic signaling cascade were also assessed. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase expression was 190% greater (P < 0.05), whereas p38 mitogen-activated protein kinase expression was 32% lower (P < 0.05), in trained vs. untrained muscle. GLUT-4 protein expression was twofold higher (P < 0.05), and the GLUT-4 vesicle-associated protein, the insulin-regulated aminopeptidase, was increased 4.7-fold (P < 0. 05) in trained muscle. In conclusion, the expression of proteins involved in signal transduction is altered in skeletal muscle from well-trained athletes. Downregulation of early components of the insulin-signaling cascade may occur in response to increased insulin sensitivity associated with endurance training.


Asunto(s)
Ejercicio Físico/fisiología , Proteínas de Transporte de Monosacáridos/metabolismo , Proteínas Musculares/fisiología , Músculo Esquelético/metabolismo , Proteínas Serina-Treonina Quinasas , Transducción de Señal/fisiología , Adulto , Aminopeptidasas/metabolismo , Citrato (si)-Sintasa/metabolismo , Cistinil Aminopeptidasa , Transportador de Glucosa de Tipo 4 , Humanos , Proteínas Sustrato del Receptor de Insulina , Péptidos y Proteínas de Señalización Intracelular , Masculino , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Fosfoproteínas/metabolismo , Educación y Entrenamiento Físico , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-akt , Receptor de Insulina/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos
8.
Transfusion ; 39(8): 845-51, 1999 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10504120

RESUMEN

BACKGROUND: A new generation of assays for the detection of human T-lymphotropic virus types I and II (HTLV-I/II) antibodies has been released. These assays incorporate HTLV-I- and HTLV-II-specific antigens, and some are based on new assay principles. Comparative evaluation data that include these new as well as previous assays are limited. STUDY DESIGN AND METHODS: Fourteen HTLV antibody assays were evaluated by using well-characterized panels of sera from Guinea-Bissau, West Africa, and Sweden. The sera included 127 HTLV-I-positive and 62 HTLV-II-positive specimens, as well as 919 consecutive negative samples. RESULTS: The sensitivity for HTLV-I was 100 percent for all assays, except one, which repeatedly missed one sample. The sensitivity for HTLV-II varied between 86 percent and 100 percent. In general, new-generation assays incorporating HTLV-II-specific antigens, and some of which are based on new assay principles, had a higher sensitivity for HTLV-II than previous assays, which mainly are based on HTLV-I antigens. The specificity was generally higher for new assays than for the previous versions. Testing of Swedish blood donor sera gave higher specificities (94-100%) than did that of African specimens (90-99.7%). Most assays had low delta values (DVs), although there was a tendency toward increased DVs for the new generation of assays. Only two of the new generation of assays came close to a combination of high sensitivity for both HTLV-I and HTLV-II, high specificity, positive and negative predictive values, and high DVs. CONCLUSION: The sensitivity for HTLV-I was generally high and appears to have improved for HTLV-II with the introduction of a new generation of assays incorporating HTLV-II-specific antigens. However, some assays still give false-negative results on HTLV-II-positive specimens. The specificities and the DVs were generally higher for the new assays than for the previous versions.


Asunto(s)
Anticuerpos Antideltaretrovirus/sangre , Virus Linfotrópico T Tipo 1 Humano/inmunología , Virus Linfotrópico T Tipo 2 Humano/inmunología , Tamizaje Masivo/normas , África Occidental , Estudios de Evaluación como Asunto , Reacciones Falso Negativas , Humanos , Sensibilidad y Especificidad , Suecia
9.
Clin Physiol ; 19(2): 135-42, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10200895

RESUMEN

We determined whether habitual cigarette smoking alters insulin-stimulated glucose transport and GLUT4 protein expression in skeletal muscle. Vastus lateralis muscle was obtained from 10 habitual cigarette smokers and 10 control subjects using an open muscle biopsy procedure. Basal 3-O-methylglucose transport was twofold higher (P < 0.01) in muscle from habitual smokers (0.05 +/- 0.08 vs. 1.04 +/- 0.19 mumol ml-1 h-1; controls vs. smokers respectively). Insulin (600 pmol l-1) increased glucose transport 2.6-fold (P > 0.05) in muscle from control subjects, whereas no significant increase was noted in habitual smokers. Skeletal muscle GLUT4 protein expression was similar between the groups. FFA levels were elevated in the smokers (264 +/- 49 vs. 748 +/- 138 mumol l-1 for control subjects vs. smokers; P < 0.05), and serum triglyceride levels were increased in the smokers (0.9 +/- 0.2 vs. 2.3 +/- 0.6 mmol l-1 for control subjects vs. smokers; P < 0.05). Skeletal muscle carnitine palmitil (acyl) transferase activity was similar between the groups, indicating that FFA transport into the mitochondria was unaltered by cigarette smoking. In conclusion, cigarette smoking appears to have a profound effect on glucose transport in skeletal muscle. Basal glucose transport is markedly elevated, whereas insulin-stimulated glucose transport is impaired. These changes cannot be explained by altered protein expression of GLUT4, but may be related to increased serum FFA and triglyceride levels. These findings highlight the importance of identifying habitual cigarette smokers in studies aimed at assessing factors that lead to alterations in lipid and glucose homeostasis in people with non-insulin-dependent diabetes mellitus (NIDDM).


Asunto(s)
Glucosa/metabolismo , Lípidos/sangre , Proteínas Musculares , Músculo Esquelético/metabolismo , Fumar/metabolismo , 3-O-Metilglucosa/metabolismo , Adulto , Glucemia/metabolismo , Carnitina O-Palmitoiltransferasa/metabolismo , Transportador de Glucosa de Tipo 4 , Humanos , Immunoblotting , Insulina/metabolismo , Lipoproteínas/sangre , Masculino , Proteínas de Transporte de Monosacáridos/biosíntesis , Consumo de Oxígeno/fisiología , Fumar/sangre
10.
Diabetes ; 48(3): 664-70, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10078575

RESUMEN

To determine whether defects in the insulin signal transduction pathway to glucose transport occur in a muscle fiber type-specific manner, post-receptor insulin-signaling events were assessed in oxidative (soleus) and glycolytic (extensor digitorum longus [EDL]) skeletal muscle from Wistar or diabetic GK rats. In soleus muscle from GK rats, maximal insulin-stimulated (120 nmol/l) glucose transport was significantly decreased, compared with that of Wistar rats. In EDL muscle from GK rats, maximal insulin-stimulated glucose transport was normal, while the submaximal response was reduced compared with that of Wistar rats. We next treated diabetic GK rats with phlorizin for 4 weeks to determine whether restoration of glycemia would lead to improved insulin signal transduction. Phlorizin treatment of GK rats resulted in full restoration of insulin-stimulated glucose transport in soleus and EDL muscle. In soleus muscle from GK rats, submaximal and maximal insulin-stimulated insulin receptor substrate (IRS)-1 tyrosine phosphorylation and IRS-1-associated phosphatidylinositol (PI) 3-kinase activity were markedly reduced, compared with that of Wistar rats, but only submaximal insulin-stimulated PI 3-kinase was restored after phlorizin treatment. In EDL muscle, insulin-stimulated IRS-1 tyrosine phosphorylation and IRS-1-associated PI-3 kinase were not altered between GK and Wistar rats. Maximal insulin-stimulated Akt (protein kinase B) kinase activity is decreased in soleus muscle from GK rats and restored upon normalization of glycemia (Krook et al., Diabetes 46:2100-2114, 1997). Here, we show that in EDL muscle from GK rats, maximal insulin-stimulated Akt kinase activity is also impaired and restored to Wistar rat levels after phlorizin treatment. In conclusion, functional defects in IRS-1 and PI 3-kinase in skeletal muscle from diabetic GK rats are fiber-type-specific, with alterations observed in oxidative, but not glycolytic, muscle. Furthermore, regardless of muscle fiber type, downstream steps to PI 3-kinase (i.e., Akt and glucose transport) are sensitive to changes in the level of glycemia.


Asunto(s)
Diabetes Mellitus Tipo 2/fisiopatología , Regulación de la Expresión Génica , Glucosa/metabolismo , Insulina/fisiología , Fibras Musculares Esqueléticas/metabolismo , Proteínas Musculares , Músculo Esquelético/metabolismo , Proteínas Serina-Treonina Quinasas , Transducción de Señal/fisiología , 3-O-Metilglucosa/farmacocinética , Animales , Transporte Biológico/efectos de los fármacos , Peso Corporal , Diabetes Mellitus Tipo 2/genética , Regulación de la Expresión Génica/efectos de los fármacos , Transportador de Glucosa de Tipo 4 , Glucógeno Sintasa/genética , Proteínas Sustrato del Receptor de Insulina , Proteínas de Transporte de Monosacáridos/genética , Fibras Musculares Esqueléticas/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Florizina/farmacología , Fosfatidilinositol 3-Quinasas/genética , Fosfatidilinositol 3-Quinasas/metabolismo , Fosfoproteínas/genética , Fosfoproteínas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-akt , Ratas , Ratas Endogámicas , Ratas Wistar , Especificidad de la Especie
11.
Tidsskr Nor Laegeforen ; 119(2): 237-41, 1999 Jan 20.
Artículo en Noruego | MEDLINE | ID: mdl-10081357

RESUMEN

Norway has been a stronghold of restrictive attitudes and scepticism towards the use of methadone in treatment of heroin addiction. A policy of nation-wide use of methadone has now been adopted. This paper gives a short history of the use of methadone, a review of present neurobiological knowledge and a description of the different approaches in methadone based treatment. Methadone treatment does not reduce opioid dependency but compensates for neurobiological complications of long-term use. This increases the ability to profit from psychosocial approaches in treatment and reduces the tendency to risk-taking and socially disturbing behaviour. Norway aims to follow the "Swedish" model in methadone policy with emphasis on high threshold, high dose treatment combined with control and systematic rehabilitative measures. This choice should be evaluated both in a comparative and in a treatment oriented perspective.


Asunto(s)
Dependencia de Heroína/rehabilitación , Metadona/uso terapéutico , Dependencia de Heroína/psicología , Historia del Siglo XX , Humanos , Metadona/historia , Noruega , Programas Médicos Regionales , Trastorno de la Conducta Social/prevención & control , Trastorno de la Conducta Social/rehabilitación
12.
FASEB J ; 12(13): 1379-89, 1998 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9761781

RESUMEN

The molecular signaling mechanisms by which muscle contractions lead to changes in glucose metabolism and gene expression remain largely undefined. We assessed whether exercise activates MAP kinase proteins (ERK1/2, SEK1, and p38 MAP kinase) as well as Akt and PYK2 in skeletal muscle from healthy volunteers obtained during and after one-leg cycle ergometry at approximately 70% VO2max. Exercise led to a marked increase in ERK1/2 phosphorylation, which rapidly decreased to resting levels upon recovery. Exercise increased phosphorylation of SEK1 and p38 MAP kinase to a lesser extent than ERK1/2. In contrast to ERK1/2, p38 MAP kinase phosphorylation was increased in nonexercised muscle upon cessation of exercise. Phosphorylation of the transcription factor CREB was increased in nonexercised muscle upon cessation of exercise. Exercise did not activate Akt or increase tyrosine phosphorylation of PYK2. Thus, exercise has divergent effects on parallel MAP kinase pathways, of which only p38 demonstrated a systemic response. However, our data do not support a role of Akt or PYK2 in exercise/contraction-induced signaling in human skeletal. Activation of the different MAP kinase pathways by physical exercise appears to be important in the regulation of transcriptional events in skeletal muscle.


Asunto(s)
Ejercicio Físico/fisiología , Proteínas Quinasas JNK Activadas por Mitógenos , MAP Quinasa Quinasa 4 , Quinasas de Proteína Quinasa Activadas por Mitógenos , Proteínas Quinasas Activadas por Mitógenos , Proteínas Musculares/metabolismo , Músculo Esquelético/metabolismo , Proteínas Quinasas/metabolismo , Proteínas Serina-Treonina Quinasas , Transducción de Señal/fisiología , Glucemia/análisis , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Activación Enzimática , Prueba de Esfuerzo , Quinasa 2 de Adhesión Focal , Regulación de la Expresión Génica/fisiología , Humanos , Insulina/sangre , Insulina/farmacología , Lactatos/sangre , Proteína Quinasa 1 Activada por Mitógenos , Proteína Quinasa 3 Activada por Mitógenos , Contracción Muscular/fisiología , Proteínas Musculares/genética , Fosforilación , Procesamiento Proteico-Postraduccional , Proteínas Tirosina Quinasas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-akt , Proteínas Quinasas p38 Activadas por Mitógenos
13.
Diabetes ; 47(8): 1281-6, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9703329

RESUMEN

The serine/threonine kinase Akt (PKB/Rac) has been implicated as playing a role in the insulin-signaling pathway to glucose transport. Little is known regarding the regulation of Akt kinase activity in insulin-sensitive tissues, such as skeletal muscle, or whether this regulation is altered in insulin-resistant states such as NIDDM. We examined the effect of insulin on Akt kinase activity in skeletal muscle from six NIDDM patients and six healthy subjects. Whole-body insulin sensitivity, assessed by the euglycemic-hyperinsulinemic clamp, was significantly lower in NIDDM subjects (P < 0.001), and this was accompanied by impaired in vitro insulin-stimulated glucose transport in skeletal muscle. In both groups, insulin induced a significant increase in Akt kinase activity, but the response to maximal insulin (60 nmol/l) was markedly reduced in skeletal muscle from NIDDM subjects (66% of control levels, P < 0.01). Impaired Akt kinase activity was not accompanied by decreased protein expression of Akt. Instead, a trend toward increased Akt expression was noted in skeletal muscle from NIDDM subjects (P < 0.1). These parallel defects in insulin-stimulated Akt kinase activity and glucose transport in diabetic skeletal muscle suggest that reduced Akt kinase activity may play a role in the development of insulin resistance in NIDDM.


Asunto(s)
Diabetes Mellitus Tipo 2/enzimología , Insulina/farmacología , Músculo Esquelético/enzimología , Proteínas Serina-Treonina Quinasas , Proteínas Proto-Oncogénicas/metabolismo , Transporte Biológico/efectos de los fármacos , Glucosa/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Proteínas Proto-Oncogénicas c-akt , Valores de Referencia
14.
BMJ ; 316(7142): 1417-22, 1998 May 09.
Artículo en Inglés | MEDLINE | ID: mdl-9572750

RESUMEN

OBJECTIVE: To analyse the cost effectiveness of a national programme to screen blood donors for infection with the human T cell leukaemia/lymphoma virus. DESIGN: Three models for calculating the costs and benefits of screening were developed. The first model analysed the cost of continuously testing all donations; the second analysed the cost of initially testing new blood donors and then retesting them after five years; the third analysed the cost of testing donors only at the time of their first donation. Patients who had received blood components from donors confirmed to be infected with the virus were offered testing. SETTING: Sweden. MAIN OUTCOME MEASURES: Prevalence of infection with the virus among blood donors, the risk of transmission of the virus, screening costs, and the outcome of infection. RESULTS: 648 497 donations were tested for the virus; 1625 samples tested positive by enzyme linked immunosorbent assay. 6 were confirmed positive by western blotting. The prevalence of infection with the virus was 2/100 000 donors. 35 patients who had received blood infected with the virus were tested; 3 were positive. The cost of testing every donation was calculated to be $3.02m (1.88m pounds); this is 18 times higher than the cost of testing new donors only, and only 1 additional positive donor would be discovered in 7 years. Regardless of the model used, screening was estimated to prevent only 1 death every 200 years at a minimum cost of $36m (22.5m pounds). CONCLUSION: Based on these estimates the Swedish National Board of Health and Welfare decided that only new blood donors would be screened for infection with the virus.


Asunto(s)
Donantes de Sangre/estadística & datos numéricos , Leucemia-Linfoma de Células T del Adulto/prevención & control , Tamizaje Masivo/economía , Adulto , Transfusión Sanguínea/economía , Western Blotting/economía , Análisis Costo-Beneficio , Ensayo de Inmunoadsorción Enzimática/economía , Humanos , Incidencia , Leucemia-Linfoma de Células T del Adulto/economía , Leucemia-Linfoma de Células T del Adulto/epidemiología , Tamizaje Masivo/métodos , Modelos Económicos , Prevalencia , Evaluación de Programas y Proyectos de Salud , Estudios Retrospectivos , Factores de Riesgo , Suecia/epidemiología , Reacción a la Transfusión
15.
Diabetes ; 46(12): 2110-4, 1997 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9392506

RESUMEN

The serine/threonine kinase Akt (protein kinase B [PKB] or related to A and C protein kinase [RAC]) has recently been implicated to play a role in the signaling pathway to glucose transport. However, little is known concerning the regulation of Akt activity in insulin-sensitive tissues such as skeletal muscle. To explore the role of hyperglycemia on Akt kinase activity in skeletal muscle, normal Wistar rats or Goto-Kakizaki (GK) diabetic rats were treated with phlorizin. Phlorizin treatment normalized fasting blood glucose and significantly improved glucose tolerance (P < 0.001) in GK rats, whereas in Wistar rats, the compound had no effect on glucose homeostasis. In soleus muscle from GK rats, maximal insulin-stimulated (120 nmol/l) Akt kinase activity was reduced by 68% (P < 0.01) and glucose transport was decreased by 39% (P < 0.05), compared with Wistar rats. Importantly, the defects at the level of Akt kinase and glucose transport were completely restored by phlorizin treatment. There was no significant difference in Akt kinase protein expression among the three groups. At a submaximal insulin concentration (2.4 nmol/l), activity of Akt kinase and glucose transport were unaltered. In conclusion, improved glucose tolerance in diabetic GK rats by phlorizin treatment fully restored insulin-stimulated activity of Akt kinase and glucose transport. Thus, hyperglycemia may directly contribute to the development of muscle insulin resistance through alterations in insulin action on Akt kinase and glucose transport.


Asunto(s)
Diabetes Mellitus Tipo 2/enzimología , Prueba de Tolerancia a la Glucosa , Glucosa/metabolismo , Insulina/farmacología , Músculo Esquelético/metabolismo , Proteínas Serina-Treonina Quinasas , Proteínas Proto-Oncogénicas/metabolismo , Animales , Transporte Biológico/efectos de los fármacos , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Resistencia a la Insulina , Masculino , Músculo Esquelético/efectos de los fármacos , Florizina/uso terapéutico , Proteínas Proto-Oncogénicas c-akt , Ratas , Ratas Mutantes
16.
Artículo en Inglés | MEDLINE | ID: mdl-9342259

RESUMEN

The prevalence and risk factors for acquisition of human T-cell lymphotropic virus type I and II (HTLV-I and II) were investigated in a prospective study of 913 injecting drug users (IDUs) in Stockholm in 1994. Epidemiologic data were recorded, and blood samples were tested for antibodies against HTLV-I and HTLV-II; human immunodeficiency virus (HIV) types 1 and 2; and hepatitis A (HAV), B (HBV), C (HCV), and D (HDV). Positive serologic results for HTLV were confirmed by Western blot (WB) and polymerase chain reaction (PCR). Of the 905 participants with conclusive HTLV-II status, 29 (3.2%) were HTLV-II positive, and all but three were of Nordic descent. None was HTLV-I infected. One person was infected as early as 1981, before HIV had reached the IDU population in Sweden. The prevalence of HTLV-II infection was 12% among HIV-1-seropositive and 1.8% among HIV-1-seronegative participants. The overall seroprevalences were 14% for HIV-1, 0% for HIV-2, 41% for HAV, 75% for HBV, 92% for HCV, and 8% for HDV. Although amphetamine has been the main injecting drug in Sweden for several decades, heroin abuse combined with a debut of injecting drugs before 1975 was identified as the most important risk factor associated with HTLV-II infection. HAV and HIV seropositivity were also independent risk factors.


Asunto(s)
Infecciones por HTLV-II/epidemiología , Abuso de Sustancias por Vía Intravenosa/complicaciones , Adulto , Factores de Edad , Femenino , Seropositividad para VIH/complicaciones , Seropositividad para VIH/epidemiología , Infecciones por HTLV-I/epidemiología , Anticuerpos Anti-HTLV-II/sangre , Infecciones por HTLV-II/complicaciones , Hepatitis A/complicaciones , Hepatitis A/epidemiología , Hepatitis Viral Humana/complicaciones , Hepatitis Viral Humana/epidemiología , Humanos , Masculino , Prevalencia , Estudios Prospectivos , Factores de Riesgo , Suecia/epidemiología
17.
J Clin Endocrinol Metab ; 81(5): 1979-83, 1996 May.
Artículo en Inglés | MEDLINE | ID: mdl-8626868

RESUMEN

Polycystic ovary syndrome (PCOS) is a common disorder characterized by chronic anovulation and infertility, hyperandrogenaemia, and frequently insulin resistance. This study investigated whether mutations in the insulin receptor gene could explain the insulin resistance in subjects with PCOS. From a total of 108 women with PCOS, a subgroup of 24 were selected on the criteria of being in the upper quartile for insulin resistance as assessed by fasting serum insulin, insulin area under the curve following 75 g oral glucose tolerance test, and endogenous glucose disposal as a measure of insulin sensitivity. An additional five normal women were also investigated. The entire coding region of the insulin receptor gene, comprising of 22 exons, was amplified by the PCR using genomic DNA and then subjected to single-stranded conformation polymorphism (SSCP) analysis to screen for single-base DNA sequence changes. DNA sequencing revealed that SSCP variants were detected in regions encompassing exons 3, 6-8, 11, 13, 15, 17, and 22. SSCP variants in regions of exons 3, 6, 7, 11, 15 and 22 were caused by nucleotide substitutions within intronic regions flanking the exon. The considerable variation seen in the 5' intron of exon 3 was found to be caused by variation in the number of (ATTT, 8-11) and (TC, 10-13) short sequence repeats. SSCP variants in exons 8 (Asp519, Ala523), 13 (Asn 838), and 17 (Tyr984, His1058) were caused by known silent polymorphisms. Southern blotting experiments excluded major gene deletions, insertions, or rearrangements. We conclude that insulin resistance in subjects with PCOS is not commonly a consequence of missense or nonsense mutations in the insulin receptor gene.


Asunto(s)
Resistencia a la Insulina/genética , Mutación , Síndrome del Ovario Poliquístico/genética , Receptor de Insulina/genética , Southern Blotting , ADN/análisis , Exones , Femenino , Humanos , Reacción en Cadena de la Polimerasa , Polimorfismo Conformacional Retorcido-Simple
19.
AIDS Care ; 7(3): 375-9, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7578312

RESUMEN

The somatic care of HIV-infected intravenous drug abusers (IVDUs) is often combined with many problems. The addict is often an unpopular patient, but society must assume responsibility for him or her and it is important to solve care problems in an appropriate way. This study was undertaken in order to investigate what kind of care addicts want when they become somatically ill. A questionnaire was given to patients who acquired HIV infection due to intravenous drug abuse, who visited an outpatient clinic for HIV-infected patients at the Department of Infectious Disease, Huddinge Hospital, Stockholm, Sweden. A total of 72 of the original 78 questionnaires could be evaluated. Thirty respondents took part in the Stockholm Methadone Programme. The patients were asked to rank the importance of professional competence among the staff. The patients ranked competence in pain treatment highest followed by competence in somatic medical care. Lower ranked, but still perceived as important, was competence in psychiatric medical care and social welfare work. Experience in treatment of addiction was ranked as less important. It can be concluded that it is fruitful to ask IVDUs about their preferences concerning care.


Asunto(s)
Infecciones por VIH/terapia , Grupo de Atención al Paciente , Rol del Enfermo , Abuso de Sustancias por Vía Intravenosa/complicaciones , Infecciones Oportunistas Relacionadas con el SIDA/psicología , Infecciones Oportunistas Relacionadas con el SIDA/terapia , Adulto , Competencia Clínica , Femenino , Infecciones por VIH/psicología , Humanos , Masculino , Persona de Mediana Edad , Cuidados Paliativos/psicología , Admisión del Paciente , Neumonía/psicología , Neumonía/terapia , Abuso de Sustancias por Vía Intravenosa/psicología , Abuso de Sustancias por Vía Intravenosa/rehabilitación , Suecia
20.
Scand J Infect Dis ; 27(6): 547-50, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-8685631

RESUMEN

Serum samples collected in 1992 from 1158 intravenous drug users (IVDUs) in Stockholm, Sweden, were tested retrospectively for antibodies to human T-lymphotropic virus type I and II (HTLV-I and II). The overall prevalence rate of HTLV infections was 2.4% (28/1158). A majority of the HTLV infections were caused by HTLV-II (27/28). A significant association between HTLV-II and HIV-1 seropositivity was found, the prevalence of HTLV-II infection being 11.4% (11/96) in HIV-seropositive individuals compared with 1.5% (16/1062) in HIV-seronegative persons (p < 0.001). All the HTLV-infected individuals were of Scandinavian origin. No significant differences in age and sex distribution were observed in HTLV-infected persons compared to seronegative individuals. This study confirms that HTLV-II infection is present in the Swedish IVDU population and the findings provide baseline information for future epidemiological studies.


Asunto(s)
Infecciones por HTLV-I/epidemiología , Infecciones por HTLV-II/epidemiología , Abuso de Sustancias por Vía Intravenosa , Adolescente , Adulto , Anciano , Ensayo de Inmunoadsorción Enzimática , Femenino , Infecciones por HTLV-I/sangre , Infecciones por HTLV-I/complicaciones , Infecciones por HTLV-II/sangre , Infecciones por HTLV-II/complicaciones , Virus Linfotrópico T Tipo 1 Humano/inmunología , Virus Linfotrópico T Tipo 2 Humano/inmunología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Pruebas Serológicas , Abuso de Sustancias por Vía Intravenosa/complicaciones , Suecia/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA